Recruiting

Early Detection of CTEPH in Patients After APE

The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic. The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Chronic tromboembolic pulmonary hypertesion in such a way as to ensure the maximum positive impact on the health of the population and high cost-effectiveness of the whole process.

ClinicalTrials.gov IDNCT06865326

PhaseNot Applicable

Enrollment500

SponsorInstitute of Health Information and Statistics of the Czech Republic

Age18 Years and older

SexALL

I'm interested View official listing

Conditions studied

Chronic Pulmonary Thromboembolism

About this study

Interventions

Other: Standardized CTEPH Screening Protocol — Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.

Primary outcomes

Positive predictive value of initial examination (Up to six months from enrollment)
CTEPH detection rates (Up to six months from enrollment)
Proportion of people with suspected CTEPH who attended a follow-up examination at a specialized pulmonary hypertension treatment centre (Up to six months from enrollment)

Eligibility information

Inclusion Criteria: * Age over 18 years * Signed consent to participate in the project and GDPR * Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy: 1. Patients with new-onset and ongoing or progressive dyspnea (min. NYHA II) after a pulmonary embolism episode or worsening of dyspnea after a pulmonary embolism episode compared to the status before the episode (at least 1 HYHA grade) or 2. Asymptomatic patients after a pulmonary embolism episode and at least one of the following risk factors: * ECHO evidence of severe PH at diagnosis of PE (PASP \>60 mmHg) * Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin) * Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems * Presence of ventriculoatrial shunt for treatment of hydrocephalus * Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease) * History of splenectomy * Myeloproliferative disorders * Chronic osteomyelitis Exclusion Criteria: * Not agreeing to participate in the project * Contraindications to treatment

Study locations

Brno University Hospital, Brno, Czechia
Havlíčkův Brod Hospital, Havlíčkův Brod, Czechia
University Hospital Hradec Králové, Hradec Králové, Czechia
Jihlava Hospital, Jihlava, Czechia
Náchod Hospital, Náchod, Czechia
University Hospital Olomouc, Olomouc, Czechia
University Hospital Ostrava, Ostrava, Czechia
Pardubice Hospital, Pardubice, Czechia
Rychnov nad Kněžnou Hospital, Rychnov nad Kněžnou, Czechia
Tábor Hospital, Tábor, Czechia

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-27.